Objective: To study the association gene of candidate NPSR1 rs324981 with sleep disorders in the open population of men 45-64 years of Novosibirsk. Methods: The study of the association candidate gene polymorphisms with sleep disorders was carried out during the examination of a random representative sample of men 45-69 years (n = 1770). The response rate was 61%. The median age is 56.5 year. Every 12 subject was selected for genotyping (n = 147). To assess the level of sleep was used a questionnaire which was filled with self-test. Statistical analysis was performed using SPSS-11.5. Results: The level of sleep disorders in the male population of 45-64 years was 79.9%. The frequency of homozygous C / C genotype of neuropeptide S (gene NPSR1 rs324981) was 19.4%, T / T genotype occurs in 27.8%, C / T genotype -52.8%.
PT654
Suvorexant induced restless legs syndrome; a case report Tomomi Ogihara, Daimei Sasayama, Shinsuke Washizuka Shinshu University, Japan Abstract Natural sleep-awake cycle is regulated by serotonin, histamine, acetylcholine, and dopamine. Orexin system is believed to play a role in controlling these systems, and its dysfunction results in narcolepsy. Suvorexant is the first dual orexin receptor antagonist (DORA) to be approved for the treatment of insomnia. We describe a patient who presented with restless legs syndrome (RLS) induced by suvorexant.
The case was an 81-year-old woman who was diagnosed with depression at the age of 77. She was in remission for some years except for insomnia, which was treated with 1 mg/ day of flunitrazepam, 0.25 mg/day of brotizolam and 8 mg/day of ramelteon. She had a history of severe RLS induced by 12.5mg/ day of quetiapine, which disappeared with the discontinuation of quetiapine. She complained of insomnia during hospitalization for an aortic valve replacement for severe aortic stenosis. Because the benzodiazepines did not sufficiently improve the insomnia, she was started on 15mg/day of suvorexant. On the first night of suvorexant treatment, she was unable to sleep well due to the crawly feelings in the legs. The uncomfortable sensation disappeared the following day but reappeared at night. Suvorexant treatment was discontinued and the RLS subsequently disappeared. To our knowledge, this is the first case of restless legs syndrome induced by suvorexant.
Orexin neurons project to the entire central nervous system including locus coeruleus, laterodorsal tegmental nucleus, pedunculopontine tegmental nucleus, basal forebrain, tuberomammillary nucleus, dorsal raphe nuclei and ventral tegmental area. These brain arousal systems project to serotonin, histamine, acetylcholine, and dopamine neurons. Suvorexant treatment may have caused the imbalance of monoamines, leading to the development of RLS in this case.
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The effectiveness of prolonged-release melatonin among primary insomnia patients whose sleep schedule was set
Boram Park, MD, Soyoung Youn, M.D., Suyeon Lee, M.D., Seockhoon Chung, MD, PhD Department of Psychiatry, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea
Abstract Objective: Prolonged-release formulation of melatonin (PRM) is approved for insomnia patients ≥ 55 years old. Taking PRM 1-2 hours before bedtime is recommended, and a 26 ~ 47% response rate was reported in France and UK. Our study purpose is to investigate the effectiveness of PRM when used for insomnia patients whose sleep schedule was set. Method: We reviewed the medical records of primary insomnia patients prescribed PRM after visiting the Psychiatry Department sleep clinic, Asan Medical Center, to obtain routinely asked information regarding sleep satisfaction, sleep-time schedule, and class and dose of sleeping pills. We selected patients who were dissatisfied with their sleep even after their sleep schedule was set before taking PRM. We analyzed satisfaction rate and treatment-emergent adverse events (TEAE) after taking PRM.
Results: Among 26 of these patients, 22 (87%) took other sleeping pills. Mean duration of taking PRM among 24 patients who were followed was 28.0 ± 13.0 days. At study endpoint, satisfaction rate to PRM was 71% (n=17) and daytime sleepiness (n=2), headache (n=1), and dizziness (n=1) were reported as TEAE. Among 20 patients who were also prescribed other sleeping pills and followed-up, 40% (n=8) could reduce their sleeping pills dosage more than 50%. Conclusion: We observed a 71% satisfaction rate to PRM when we prescribed it to patients who were dissatisfied with sleep even after their sleep schedule was set. TEAE were not prevalent and 40% of patients who simultaneously took other sleeping pills could reduce the dosage. It is important to select patients who can be well-improved when PRM is prescribed for them.
